Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Revenue projections:

Eli Lilly and Company's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio	1.355000
forwardPE	24.523623
debtToEquity	162.071000
earningsGrowth	0.262000
revenueGrowth	0.477000
grossMargins	0.833990
operatingMargins	0.542220
trailingEps	29.380000
forwardEps	47.566790

LLY's current ratio of 1.355 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that LLY is financially well-prepared to meet its liabilities without difficulty.
Eli Lilly and Company's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
LLY's high debt-to-equity ratio reveals that the company is heavily reliant on debt for financing. This high level of leverage increases the risk of financial strain if profits decline or interest rates rise.
Positive earnings and revenue growth for LLY point to expected business expansion. The company is projected to continue growing its operations, as increasing profits and sales highlight a strong trajectory for further growth in the future.
LLY's positive gross and operating margins highlight its strong profitability. The company's ability to control costs while generating revenue indicates efficient operations and a healthy financial position.
LLY's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in LLY's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Over time, LLY's price projections have been revised higher, signaling growing confidence in the company's future. This upward trend suggests analysts anticipate strong performance and increased market value for LLY.

Insider Transactions:

39 transactions were made to sell LLY shares, with market price of 960.3166613456531.There were 4 buy transactions of LLY stock, with market price at 656.6999969482422 per share.Insider transactions show no strong upward or downward movement, offering little insight into the company's future performance or strategic direction.

Recommendation changes over time:

The analysts' recent buy bias for LLY indicates strong confidence in the stock's future performance. This could encourage more investors to view LLY as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.